For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and ...

This morning, at 7 AM, the civilian ship Sea Eye 4 arrived in Naples with 41 migrants on board (including some minors) coming ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...